BMC Cancer最新文献

{"title":"Impact of metabolic and nutritional disorders on the synergy between radiotherapy and immunotherapy in non-small-cell lung cancer.","authors":"Haiyan Chen, Yaner Yu, Shuangqiu Zhu, Jian Zhao, Yan Ma, Zhifei Huang, Hao Jiang, Qichun Wei","doi":"10.1186/s12885-025-14278-7","DOIUrl":"10.1186/s12885-025-14278-7","url":null,"abstract":"<p><strong>Background: </strong>Patient conditions including metabolic and nutritional status were reported to be prognostic or predictive biomarkers of anti-cancer treatment, while little attention has been paid to its association with the synergistic effect of radiotherapy (RT) and immune checkpoint inhibitors (ICIs).</p><p><strong>Methods: </strong>Metastatic non-small-cell lung cancer (mNSCLC) patients who received concurrent RT and ICIs between 2018 and 2023 were included in this study. In addition, mNSCLC patients treated with ICIs alone were enrolled to confirm the synergetic effect of RT and ICIs. Clinicopathological, metabolic and nutritional factors were collected to analyze their influence on progression-free survival (PFS), overall survival and abscopal control time. Abdominal CT was used to obtain body composition data including abdominal obesity and muscle mass.</p><p><strong>Results: </strong>A total of 96 mNSCLC patients who received RT concurrent with ICIs were included, and a synergistic effect of significantly improved PFS was observed when compared with patients treated with ICIs alone. Among patients undergoing concurrent RT and ICIs, both total adipose area(HR = 2.81,P = 0.029) and prognosis nutritional index (HR = 0.24, P<0.001) were confirmed as independent positive prognostic markers for PFS. Later-line of immunotherapy (HR = 3.67, P = 0.006), low visceral-to-subcutaneous ratio (VSR, HR = 5.53, P = 0.002), high total adipose area (HR = 5.21, P = 0.0016) and high prognostic nutritional index (HR = 0.24, P = 0.002) were independent risk factors for abscopal progression. Then, we established a scoring system consisting of metabolic and nutritional factors to stratify patients into three groups. Patients with non-visceral obesity and good nutrition status have the longest PFS and abscopal control survival, while patients with poor nutritional status regardless of body composition represent the worst prognosis.</p><p><strong>Conclusion: </strong>Metabolic and nutritional status, particularly the combined assessment of body composition and nutritional index, serves as a valuable predictor for the synergistic efficacy of concurrent RT and ICIs.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"948"},"PeriodicalIF":3.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The safety and feasibility of multiple intrathecal injections of allogenic NK cells in pediatrics with refractory/recurrent brain tumors.","authors":"Hamid Mahdizadeh, Amirhossein Izadpanah, Yasaman Nouri, Parisa Shams, Delbar Daneshjou, Alireza Aziz Ahari, Alireza Tabibkhooei, Hamidreza Haghighatkhah, Massoud Vosough, Pooya Faranoush, Masoumeh Azimi, Saba Yousefi, Atefeh Barzegari, Alireza Khosravani, Niloufar Shayan Asl, Mohammad Faranoush, Marzieh Ebrahimi","doi":"10.1186/s12885-025-14314-6","DOIUrl":"10.1186/s12885-025-14314-6","url":null,"abstract":"<p><strong>Background: </strong>Pediatric glioma is a rare condition that can lead to significant mortality and morbidity due to its high recurrence rate. This study is a phase I nonrandomized clinical trial that was conducted to assess the safety, feasibility, and potential efficacy of the intrathecal (IT) injection of multiple doses of allogenic NK cells in pediatric patients with refractory/recurrent gliomas.</p><p><strong>Methods: </strong>Allogeneic NK cells were isolated from random healthy unrelated donors via positive selection of CD56 + cells. Nine patients were selected according to the inclusion criteria and received weekly doses of up to 10 doses of 5 × 10⁷ NK cells/injection. Adverse events grading was done based on Common Terminology Criteria for Adverse Events (CTCAE) Check lists. The size of the tumor, degree of spinal spreading and duration of relapse during 18 month followup were considered components of efficacy. Additionally, six patients who received conventional treatment were selected retrospectively.</p><p><strong>Results: </strong>Multiple intrathecal injections of allogeneic NK cells in pediatric gliomas were safe, without any serious adverse events (SAEs). The most prevalent AEs were headache [29% (17% grade 1 and 13% grade 2)], fever and chills [21% (17% grade 1 and 4% grade 2)], vomiting [13% grade 2], and back pain [12% (4% grade 1 and 8% grade 2)]. 18 months of follow-up, among the five patients in the intervention group who were still alive (August 7, 2024), three exhibited stable disease (SD), one had progressive disease (PD), and one experienced a partial response (PR) with a reduction in tumor size. Among the four deceased patients, two died due to tumor progression, and two died due to infections. In the retrospective control group, five out of six patients developed PD and leptomeningeal spread (LMS), four of whom died, and one patient showed radiological evidence of a complete response (CR). Cerebrospinal fluid (CSF) analysis revealed increases in the percentages of NK and T cells and significant reductions in the levels of IFN-γ and TNF-α.</p><p><strong>Conclusions: </strong>Multiple intrathecal injections of allogeneic NK cells are safe and feasible in pediatric patients with refractory/recurrent gliomas. Although we reported a reduction in recurrence episodes and an increase in overall survival, further studies with extended follow-up periods and appropriate control groups are necessary to assess the efficacy of NK cell therapy in these patients.</p><p><strong>Trial registration: </strong>The trial was registered on the Iranian Registry of Clinical Trials (IRCT20170122032121N6), Date 2021-11-19.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"952"},"PeriodicalIF":3.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adequacy of pain management among advanced cancer patients with solid tumors attending palliative care centers in Dar es Salaam.","authors":"Judith Mwijage, Willbroad Kyejo, Davis Rubagumya, Thabit Kombo, Blessing Mathew, Faisal Hooda, Mandela Makakala, Eunice Pallangyo, Harrison Chuwa","doi":"10.1186/s12885-025-14385-5","DOIUrl":"10.1186/s12885-025-14385-5","url":null,"abstract":"<p><strong>Background: </strong>Cancer pain presents a universal challenge for patients and their families, significantly impacting quality of life. While observational studies suggest an increase in palliative care programs in Tanzania, the adequacy of pain control for cancer patients remains underexplored. Addressing this gap is crucial for enhancing patient well-being and care quality.</p><p><strong>Methodology: </strong>This analytical cross-sectional study, conducted from October to December 2021 in Dar es Salaam, Tanzania, involved 332 advanced cancer patients with solid tumors from the Aga Khan Hospital and Ocean Road Cancer Institute. A structured, interviewer-administered questionnaire comprising demographic data and factors influencing cancer-related pain (CRP) management was utilized. Additionally, the Brief Pain Inventory Short Form (BPI-SF) assessed pain intensity and interference. Statistical analysis, including chi-square tests and logistic regression, was performed using SPSS version 25 to evaluate factors associated with adequate CRP management.</p><p><strong>Results: </strong>Among 332 participants, 199 (59.9%) experienced adequate pain management, with prevalence notably higher among females, patients from Aga Khan Hospital, divorced, employed, and tertiary-educated individuals. Multivariable analysis identified sex, employment status, and education level as significant predictors of adequate pain management, with females having twice the likelihood of adequacy compared to males (OR: 1.96; 95%CI: 1.06-3.66; p = 0.033). Self-employed participants had significantly lower odds of adequate pain management compared to the employed (OR = 0.08; 95%CI: 0.01-0.33; p = 0.002), while unemployment was associated with a 91% lower likelihood of adequacy (OR = 0.09; 95%CI: 0.01-0.42; p = 0.006). Furthermore, individuals with primary education were 2.47 times more likely to report adequate pain management compared to those with nonformal education (OR: 2.47; 95%CI: 1.16-5.43; p = 0.021).</p><p><strong>Conclusion: </strong>The study highlights inadequate CRP management in Tanzania and emphasizes the influence of patient-related factors such as sex, employment status, and education level. These findings underscore the importance of tailored interventions to address disparities and enhance pain management strategies for cancer patients. Efforts to improve CRP management should consider sociodemographic factors to optimize care delivery and alleviate patient suffering effectively.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"949"},"PeriodicalIF":3.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term impact of delayed surgical treatment on the prognosis of patients with T1bN1-stage PTC: a retrospective cohort study.","authors":"Hao Gong, Tianyuchen Jiang, Yi Yang, Yuhan Jiang, Zhujuan Wu, Anping Su","doi":"10.1186/s12885-025-14371-x","DOIUrl":"10.1186/s12885-025-14371-x","url":null,"abstract":"<p><strong>Background: </strong>As the incidence of papillary thyroid carcinoma (PTC) increases, optimal timing for surgical interventions remains undefined. While surgical delays are known to affect prognosis adversely in various cancers, their impact on PTC is controversial.</p><p><strong>Methods: </strong>A retrospective study was conducted on 478 T1bN1-stage PTC patients treated at West China Hospital from January 2020 to May 2022. Patients underwent thyroidectomy with lymph node dissection and were categorized into three groups based on surgical delay: ≤90 days (group A, n = 264), > 90-180 days (group B, n = 92), and > 180 days (group C, n = 122). Additionally, patients were reclassified into two groups based on a one-year threshold: ≤365 days (group D, n = 420) and > 365 days (group E, n = 58). Tumor metastasis rates and postoperative complications were analyzed across these groups.</p><p><strong>Results: </strong>The median surgical delay was 79 days, and the median follow-up was 1362 days. Tumor metastasis occurred in 1.67% (8 patients), while postoperative complications occurred in 5.65% (27 patients). Metastasis rates were 1.89%, 1.09%, and 1.64%, and complication rates were 5.68%, 4.35%, and 6.56% for groups A, B, and C, respectively. No statistically significant differences were observed in metastasis or complication rates among the three groups. Similarly, no significant differences were found between groups D and E in tumor metastasis (p = 1.000) or complication rates (p = 0.555).</p><p><strong>Conclusion: </strong>Delayed surgery was not associated with significantly increased short-term tumor metastasis or postoperative complication rates in patients with T1bN1-stage PTC.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"950"},"PeriodicalIF":3.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Deep learning network enhances imaging quality of low-b-value diffusion-weighted imaging and improves lesion detection in prostate cancer.","authors":"Zheng Liu, Wei-Jie Gu, Fang-Ning Wan, Zhang-Zhe Chen, Yun-Yi Kong, Xiao-Hang Liu, Ding-Wei Ye, Bo Dai","doi":"10.1186/s12885-025-14354-y","DOIUrl":"10.1186/s12885-025-14354-y","url":null,"abstract":"<p><strong>Background: </strong>Diffusion-weighted imaging with higher b-value improves detection rate for prostate cancer lesions. However, obtaining high b-value DWI requires more advanced hardware and software configuration. Here we use a novel deep learning network, NAFNet, to generate a deep learning reconstructed (DLR₁₅₀₀) images from 800 b-value to mimic 1500 b-value images, and to evaluate its performance and lesion detection improvements based on whole-slide images (WSI).</p><p><strong>Methods: </strong>We enrolled 303 prostate cancer patients with both 800 and 1500 b-values from Fudan University Shanghai Cancer Centre between 2017 and 2020. We assigned these patients to the training and validation set in a 2:1 ratio. The testing set included 36 prostate cancer patients from an independent institute who had only preoperative DWI at 800 b-value. Two senior radiology doctors and two junior radiology doctors read and delineated cancer lesions on DLR₁₅₀₀, original 800 and 1500 b-values DWI images. WSI were used as the ground truth to assess the lesion detection improvement of DLR₁₅₀₀ images in the testing set.</p><p><strong>Results: </strong>After training and generating, within junior radiology doctors, the diagnostic AUC based on DLR₁₅₀₀ images is not inferior to that based on 1500 b-value images (0.832 (0.788-0.876) vs. 0.821 (0.747-0.899), P = 0.824). The same phenomenon is also observed in senior radiology doctors. Furthermore, in the testing set, DLR₁₅₀₀ images could significantly enhance junior radiology doctors' diagnostic performance than 800 b-value images (0.848 (0.758-0.938) vs. 0.752 (0.661-0.843), P = 0.043).</p><p><strong>Conclusions: </strong>DLR₁₅₀₀ DWIs were comparable in quality to original 1500 b-value images within both junior and senior radiology doctors. NAFNet based DWI enhancement can significantly improve the image quality of 800 b-value DWI, and therefore promote the accuracy of prostate cancer lesion detection for junior radiology doctors.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"953"},"PeriodicalIF":3.4,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12117842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144156573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pan-cancer analysis of homologous recombination deficiency and homologous recombination repair-associated gene alterations in solid tumors from a large Asian cohort.","authors":"Lili Ren, Runsi Yao, Ting Hou, Chenglin Liu, Fei Zhao, Xiaojun Chen, Zhou Zhang, Yan Huang","doi":"10.1186/s12885-025-14267-w","DOIUrl":"10.1186/s12885-025-14267-w","url":null,"abstract":"<p><strong>Background: </strong>Homologous recombination deficiency (HRD) is associated with sensitivity to platinum-based chemotherapy and PARP inhibitors in BRCA-associated cancers, including ovarian, breast, prostate, and pancreatic cancers. This study explores HRD and homologous recombination repair (HRR) gene alterations in a pan-cancer cohort to guide precision oncology.</p><p><strong>Methods: </strong>Clinical and genomic data from 9,262 patients with 17 solid tumor types were analyzed using the OncoScreen^TM Plus kit. HRD scores, biallelic HRR and tumor suppressor gene alterations, and their clinical correlations were evaluated.</p><p><strong>Results: </strong>HRD scores varied across cancer types, all showing a long tail in distribution. The prevalence of pathogenic alterations in pan-cancer HRR was 21.3%, with 13.7% of the cases having an HRD score ≥42. HRD-related events (LOH, LST, and TAI) exhibited similarities and cancer-specific patterns at the chromosomal arm level. Biallelic loss of HRR genes, especially BRCA1, BRCA2, RAD51D, RAD51 C, and PPP2R2 A was linked to higher HRD scores in BRCA-associated cancers, while BARD1, RAD51D, RAD54L, BRCA1, and MRE11 were associated with elevated HRD scores in in other cancer types (non-BRCA cancers). TP53 biallelic alterations, with or without HRR alterations, were linked to increased HRD scores. Higher HRD scores were associated with late-stage, older, metastatic, PD-L1 positive, non-MSI-H/non-POLE samples were correlated with genomic instability indexes, such as structural chromosomal instability (SCIN), weighted genome instability index (WGII), and whole-genome doubling (WGD).</p><p><strong>Conclusions: </strong>This is the largest pan-cancer HRD study in an Asian population, providing insights for future HRD testing and targeted therapy.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"946"},"PeriodicalIF":3.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A non-invasive nomogram for the prediction of poor prognosis of hepatocellular carcinoma based on the novel marker Interleukin-41.","authors":"Zihan Mu, Jiaojiao Su, Jiuhua Yi, Rui Fan, Jiayuan Yin, Yazhao Li, Bowen Yao","doi":"10.1186/s12885-025-14344-0","DOIUrl":"10.1186/s12885-025-14344-0","url":null,"abstract":"<p><p>Death and tumor recurrence are both important adverse prognostic factors for hepatocellular carcinoma(HCC) patients. This article aims to discuss the risk factors for recurrence and death in patients with HCC after R0 resection, and to establish a nomogram model for predicting the recurrence and death of HCC patients.A total of 224 HCC patients after R0 resection were enrolled and divided into a training cohort (n = 149) and a validation cohort (n = 75) The risk factors for recurrence and death were determined based on cox regression analysis. A nomogram containing independent risk predictors was established and validated.The recurrence rate of 224 cases of HCC after R0 resection was 43.30%. The high expression of interleukin-41(IL41) (HR = 2.446, P = 0.000), intratumoral artery (HR = 1.862, P = 0.005), and MVI1 subgroup of microvascular invasion(MVI) grade (HR = 1.541, P = 0.031) are independent risk factors associated with recurrence after resection of HCC. The mortality rate was 15.63%. The high expression of IL-41 (HR = 4.679, P = 0.000), tumor size ≥ 5 cm (HR = 3.745, P = 0.001), and Aspartate transaminase(AST) concentration 45-90u/L (HR = 2.837, P = 0.015) are independent risk factors associated with mortality. Interleukin-41(IL-41), microvascular invasion(MVI), and intratumoral artery are independent risk factors for recurrence after resection of hepatocellular carcinoma. IL-41, tumor size, and Aspartate transaminase(AST) are independent risk factors for death after resection of hepatocellular carcinoma. We developed and validated two multivariate nomograms, and conducted validation. The nomogram models have achieved ideal results in predicting the recurrence and death of HCC patients.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"941"},"PeriodicalIF":3.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of one-year recurrence among breast cancer patients undergone surgery using artificial intelligence-based algorithms: a retrospective study on prognostic factors.","authors":"Raoof Nopour","doi":"10.1186/s12885-025-14369-5","DOIUrl":"10.1186/s12885-025-14369-5","url":null,"abstract":"<p><strong>Background and aim: </strong>Breast cancer is highly prevalent, with an increasing trend in women globally. Although the survival of breast cancer is relatively high, the recurrence rate is also high, demanding effective predictive solutions to breast cancer prognosis among post-operative patients. So far, Artificial intelligence algorithms integrated with various clinical data have demonstrated potential predictive capability regarding breast cancer recurrence.</p><p><strong>Objective: </strong>This study aims to specifically conduct a predictive analysis of one-year recurrence of breast cancer by comparing and analyzing different machine learning and deep learning algorithms trained by structural prognostic data.</p><p><strong>Materials and methods: </strong>This retrospective study was carried out using one database, including 1156 post-operative breast cancer data from 30 January 2020 to 30 December 2022, in three clinical centers in Tehran City. The inclusion criteria were patients who had undergone at least one surgery, had at least one year of medical records, and did not have other conditions. The patients who were diagnosed with malignant BC and had undergone adjuvant therapies without surgery were excluded from the study. Twenty-three prognostic factors were utilized to train algorithms to establish prediction models for the one-year recurrence of breast cancer. The data were analyzed using univariate and adjusted correlation-based methods and chosen machine learning and deep learning algorithms. The discrimination, calibration, and clinical utility were leveraged to assess the algorithms' performance efficiency. The SHapley Additive exPlanations plot was generated to identify the prominent prognostic factors affecting the one-year recurrence of breast cancer.</p><p><strong>Results: </strong>Totally, 445 relapsed and 711 non-relapsed cases were utilized in this study. Our empirical study showed that the random forest with a positive predictive value of 0.96, negative predictive value of 0.92, sensitivity of 0.92, specificity of 0.96, accuracy of 0.94, F-score of 0.94, area under the receiver operator characteristics curve of 0.919 was the best-performing model for predicting the breast cancer recurrence. As the analysis of SHapley Additive exPlanations indicated, the tumor grade, HER-2, and the number of lymph nodes involved were more significant predictors.</p><p><strong>Conclusion: </strong>The current study demonstrated the potential predictive power of the random forest for early predicting tumors among breast cancer patients who have undergone surgery and its utility in enhancing decision-making in clinical environments. It is crucial in promoting the prognosis, more effectively choosing therapies, augmenting post-operative breast cancer patients' survival, and controlling the limited healthcare resources.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"940"},"PeriodicalIF":3.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105147/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhanced anti-cancer effect of AMTB hydrochloride via chitosan nanoparticles in pancreatic cancer.","authors":"Jiefeng Liu, Yujing Gong, Xinyu Zeng, Miao He, Bin He, Wenbin Gao, Yong Gao","doi":"10.1186/s12885-025-14356-w","DOIUrl":"10.1186/s12885-025-14356-w","url":null,"abstract":"<p><p>Pancreatic cancer is a malignancy with poor prognosis and high mortality. This study investigated the use of chitosan nanoparticles (CS-NPs) to encapsulate AMTB, a TRPM8 inhibitor, as a novel strategy to enhance therapeutic efficacy in pancreatic cancer. TRPM8 was overexpressed in pancreatic cancer tissues and associated with poor patient prognosis. AMTB inhibited pancreatic cancer cell proliferation, migration, and invasion by suppressing the EMT process and MMP2/9 expression. CS-NPs@AMTB were successfully synthesized, exhibiting excellent drug release profiles and stronger anti-tumor effects than free AMTB. Both AMTB and CS-NPs@AMTB demonstrated favorable biological safety. This is the first study to apply chitosan nanoparticles for AMTB delivery in pancreatic cancer, significantly enhancing its anti-tumor and anti-metastatic effects (ahout 70% reduction in tumor size). These findings suggest that CS-NPs@AMTB might overcome current therapeutic limitations by improving drug efficacy and targeting metastasis in pancreatic cancer. With further validation through preclinical and clinical studies, this nanoparticle-based delivery strategy holds promise for integration into future therapeutic regimens and personalized treatment approaches.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"944"},"PeriodicalIF":3.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peer2Me - impact of peer support on self-efficacy in young adult cancer survivors (YA-CS): findings from a comprehensive cohort design.","authors":"Hannah Brock, Sarah Dwinger, Michael Friedrich, Annekathrin Sender, Kristina Geue, Anja Mehnert-Theuerkauf, Corinna Bergelt, Diana Richter","doi":"10.1186/s12885-025-14323-5","DOIUrl":"10.1186/s12885-025-14323-5","url":null,"abstract":"<p><strong>Background: </strong>Numerous studies suggest that young adult cancer survivors (YA-CS) experience unmet needs regarding informational exchange about their disease and emotional support from peers. Currently, there is a lack of evaluated peer support interventions in Germany. This study aimed to evaluate the effectiveness of \"Peer2Me\", a three-month one-to-one peer mentoring program, designed to improve self-efficacy among YA-CS.</p><p><strong>Methods: </strong>This study conducted a bi-center comprehensive cohort design and enrolled YA-CS (18-39 years old) undergoing acute treatment in Leipzig and Hamburg (Germany) across all tumour entities diagnosed within the last six months. YA-CS were allocated by preference to the intervention (IG, receiving peer mentoring) and comparison group (CG, care as usual). Following mentor training, tandems were matched by diagnosis, age, and gender. YA-CS completed questionnaires at baseline (t1), post-intervention (3 months later, t2) and three months post-intervention (t3). The primary outcome was self-efficacy measured with the Generalized Self-Efficacy Scale (GSES) and the Cancer Behaviour Inventory (CBI-B). Statistical analyses included mixed-design ANOVA and ANCOVA, controlling for baseline scores.</p><p><strong>Results: </strong>Out of 274 eligible YA-CS, a total of 106 YA-CS (IG: n = 77, CG: n = 29) completed the study. Two-thirds of YA-CS (66.7%) expressed a clear preference to be allocated to the IG. Baseline differences in coping behaviors were noted, with the IG demonstrating lower scores, suggesting a higher need for support. The ANCOVA revealed no group effects for the change of mean GSES scores from t1 to t2 (p =.897) or from t1 to t3 (p =.779). Also, no significant differences in the improvement of mean CBI-B scores between groups could be found from t1 to t2 (p =.903) or from t1 to t3 (p =.995).</p><p><strong>Conclusions: </strong>The \"Peer2Me\" program did not demonstrate a significant effect on improving self-efficacy among YA-CS during acute treatment. Although interest in peer mentoring was high, the intervention showed no measurable benefit in comparison with standard care. While the need for support was evident, further research is required to optimize peer interventions for this group.</p><p><strong>Trial registration: </strong>The study was retrospectively registered on February 4, 2022 at clinicaltrials.gov (NCT05336318).</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"943"},"PeriodicalIF":3.4,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}